WO2006113360A3 - Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor(tfpi) - Google Patents

Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor(tfpi) Download PDF

Info

Publication number
WO2006113360A3
WO2006113360A3 PCT/US2006/013890 US2006013890W WO2006113360A3 WO 2006113360 A3 WO2006113360 A3 WO 2006113360A3 US 2006013890 W US2006013890 W US 2006013890W WO 2006113360 A3 WO2006113360 A3 WO 2006113360A3
Authority
WO
WIPO (PCT)
Prior art keywords
tfpi
administration
tissue factor
pathway inhibitor
factor pathway
Prior art date
Application number
PCT/US2006/013890
Other languages
French (fr)
Other versions
WO2006113360A2 (en
Inventor
Abla Creasey
Original Assignee
Novartis Vaccines & Diagnostic
Abla Creasey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic, Abla Creasey filed Critical Novartis Vaccines & Diagnostic
Priority to AU2006236698A priority Critical patent/AU2006236698A1/en
Priority to BRPI0610549-1A priority patent/BRPI0610549A2/en
Priority to JP2008506694A priority patent/JP2008536859A/en
Priority to EP06750055A priority patent/EP1871408A2/en
Priority to MX2007012619A priority patent/MX2007012619A/en
Priority to CA002605057A priority patent/CA2605057A1/en
Publication of WO2006113360A2 publication Critical patent/WO2006113360A2/en
Publication of WO2006113360A3 publication Critical patent/WO2006113360A3/en
Priority to IL186548A priority patent/IL186548A0/en
Priority to TNP2007000386A priority patent/TNSN07386A1/en
Priority to NO20075898A priority patent/NO20075898L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Methods for prophylactically or therapeutically treating severe pneumonia involve administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog, preferably at low doses to avoid adverse side effects.
PCT/US2006/013890 2005-04-15 2006-04-14 Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor(tfpi) WO2006113360A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2006236698A AU2006236698A1 (en) 2005-04-15 2006-04-14 Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor(TFPI)
BRPI0610549-1A BRPI0610549A2 (en) 2005-04-15 2006-04-14 treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
JP2008506694A JP2008536859A (en) 2005-04-15 2006-04-14 Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (TFPI)
EP06750055A EP1871408A2 (en) 2005-04-15 2006-04-14 Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor(tfpi)
MX2007012619A MX2007012619A (en) 2005-04-15 2006-04-14 Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor(tfpi).
CA002605057A CA2605057A1 (en) 2005-04-15 2006-04-14 Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor(tfpi)
IL186548A IL186548A0 (en) 2005-04-15 2007-10-10 Treatment of severe community-acquired pneumonia by administration of tissue factory pathway inhibitor(tfpi)
TNP2007000386A TNSN07386A1 (en) 2005-04-15 2007-10-11 Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
NO20075898A NO20075898L (en) 2005-04-15 2007-11-15 Treatment of community acquired pneumonia by administration of tissue factor pathway inhibitor (TFPI)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67146605P 2005-04-15 2005-04-15
US60/671,466 2005-04-15

Publications (2)

Publication Number Publication Date
WO2006113360A2 WO2006113360A2 (en) 2006-10-26
WO2006113360A3 true WO2006113360A3 (en) 2007-04-12

Family

ID=36951247

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/013890 WO2006113360A2 (en) 2005-04-15 2006-04-14 Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor(tfpi)

Country Status (13)

Country Link
EP (1) EP1871408A2 (en)
JP (1) JP2008536859A (en)
KR (1) KR20080033151A (en)
CN (1) CN101180074A (en)
AU (1) AU2006236698A1 (en)
BR (1) BRPI0610549A2 (en)
CA (1) CA2605057A1 (en)
IL (1) IL186548A0 (en)
MX (1) MX2007012619A (en)
RU (1) RU2007142192A (en)
TN (1) TNSN07386A1 (en)
WO (1) WO2006113360A2 (en)
ZA (1) ZA200708700B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009129164A1 (en) * 2008-04-15 2009-10-22 Novartis Ag Pharmaceutical combinations of tfpi-fragments and an antibiotic

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032904A2 (en) * 2001-10-15 2003-04-24 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032904A2 (en) * 2001-10-15 2003-04-24 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)

Also Published As

Publication number Publication date
EP1871408A2 (en) 2008-01-02
JP2008536859A (en) 2008-09-11
RU2007142192A (en) 2009-05-20
IL186548A0 (en) 2008-01-20
ZA200708700B (en) 2008-12-31
WO2006113360A2 (en) 2006-10-26
MX2007012619A (en) 2008-01-11
KR20080033151A (en) 2008-04-16
AU2006236698A1 (en) 2006-10-26
CA2605057A1 (en) 2006-10-26
BRPI0610549A2 (en) 2010-07-06
TNSN07386A1 (en) 2009-03-17
CN101180074A (en) 2008-05-14

Similar Documents

Publication Publication Date Title
WO2006122139A3 (en) Use of tfpi to treat severe bacterial infections
WO2003032904A3 (en) Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2009039397A3 (en) Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
WO2009064460A3 (en) Gastrointestinal delivery systems
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
HK1120409A1 (en) Treatment of diseases by subcutaneous administration of a vegf antagonist
WO2009034134A3 (en) Use of natriuretic peptides for treating angioedema syndromes
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
WO2010068810A3 (en) Certain substituted amides, method of making, and method of use thereof
MX346186B (en) Protein kinase inhibitors.
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2008045378A3 (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin
WO2006121995A3 (en) Methods for treating nephrolithiasis
WO2005123777A3 (en) Method of treating granuloma annulare or sarcoid
WO2005110059A3 (en) Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
WO2007104933A8 (en) Chemical compounds
WO2006113360A3 (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor(tfpi)
WO2007092436A3 (en) Compounds for treating inflammatory disorders, demyelinating disorders and cancers
WO2004087880A3 (en) Compounds and their use to treat diabetes and related disorders
WO2006124544A3 (en) Use of tyrosine kinase inhibitors in the treatment of metabolic disorders
WO2008016665A3 (en) Imidazoacridine compounds for treating flt3 -mediated disorders
WO2007116297A3 (en) Use of aminapthone for the preparation of a medicament for treating arteriophaties

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680017339.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 12007502225

Country of ref document: PH

Ref document number: 562345

Country of ref document: NZ

Ref document number: 2006236698

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 186548

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/012619

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2008506694

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2605057

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006750055

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006236698

Country of ref document: AU

Date of ref document: 20060414

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2007000707

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2007142192

Country of ref document: RU

Ref document number: 1020077026568

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06750055

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0610549

Country of ref document: BR

Kind code of ref document: A2